These observations are concordant with large‐scale Mendelian randomization studies that have shown that inhibiting IL‐6 signalling could reduce the risk of developing CHD 53 whilst inhibiting IL‐1 α/β may increase the risk of CHD 26. Here, IL1B is linked to coronary artery disorder.